Results 51 to 60 of about 8,936 (199)
ABSTRACT The PreserFlo MicroShunt is a subconjunctival glaucoma drainage device designed to reduce intraocular pressure (IOP) via a minimally invasive approach. However, device failure due to bleb fibrosis remains a significant clinical challenge, especially when initial revision surgery is unsuccessful.
Qian Wei, Frank G. Holz, Karl Mercieca
wiley +1 more source
INTRODUCTION: Pseudoexfoliation (PXM) is a fibrillar material deposited in the anterior chamber of the eye and can cause disintegration of zonules and make pupillary dilatation difficult.
Thanigasalam Thevi, Adinegara Lutfi Abas
doaj +1 more source
INTRODUCTION[|]The aim of this study was to evaluate the effects of cataract surgery on anterior segment parameters and intraocular pressure (IOP) in non-glaucomatous pseudoexfoliation syndrome (PXS) eyes.[¤]METHODS[|]The cohort consisted of 65 patients ...
Sevinc Sahin Atik +3 more
doaj +1 more source
Matrix Metalloproteinases and Glaucoma Treatment. [PDF]
Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade extracellular matrix (ECM) components such as collagen and have important roles in multiple biological processes, including development and tissue remodeling, both in ...
Dibas, Mohammed +3 more
core
ABSTRACT Background The bleb‐forming surgical spectrum in open‐angle glaucoma has recently been expanded by novel surgical approaches. Through a medical device implantation (Xen Gel Stent (XGI) or Preserflo Microshunt (PMI)), these procedures aim at more standardised aqueous humour shunting and an intra‐ and postoperative risk reduction ...
Martin Kallab +3 more
wiley +1 more source
PSEUDOEXFOLIATIVE SYNDROME AS A TRIGGER FOR PSEUDOEXFOLIATIVE GLAUCOMA
Glaucoma is one of the leading causes of blindness and disability worldwide. Pseudoexfoliative glaucoma is known to be the most aggressive and difficult-to-treat form of secondary glaucoma. According to the literature, pseudoexfoliative glaucoma occurs in 25-30% of cases among all open-angle glaucoma.
I. M. Bezkorovaуna, Eddine Jouini Dhia
openaire +2 more sources
Minimally Invasive Glaucoma Surgery: Is It Here to Stay?
ABSTRACT The advent of minimally invasive glaucoma surgery (MIGS) has expanded the treatment options available for glaucoma by providing options for reducing intraocular pressure without the serious complication profile associated with incisional glaucoma surgery.
Neeranjali Jain, Jennifer C. Fan Gaskin
wiley +1 more source
Abstract Purpose This trial evaluated the noninferiority of a relaxed compared to a strict treat‐and‐extend treatment strategy in patients with neovascular Age‐related macular degeneration (AMD). Methods Multicenter, randomized, controlled, phase IV, non‐inferiority clinical trial.
Damian Jaggi +9 more
wiley +1 more source
Selective Laser Trabeculoplasty in the Treatment of Pseudoexfoliation Glaucoma in Patients Allergic to all Anti-Glaucoma Drops [PDF]
Secondary chronic open-angle glaucoma associated with pseudoexfoliation (PEX) syndrome accounts for approximately 25% of all glaucomas and represents the most common identifiable cause of glaucoma overall.
Iva Dekaris +4 more
core +1 more source
First postoperative day review after uneventful phacoemulsification cataract surgery: Is it necessary? [PDF]
BACKGROUND: Our purpose was to examine the value of the first postoperative day review after uneventful phacoemulsification cataract surgery.
Evgenia Kanonidou +3 more
core +1 more source

